Treatment of Invasive Fungal Infections in Patients With Solid Organ Transplants

The number of patients undergoing solid organ transplantation is increasing. Invasive fungal infection (IFI) is an important cause of graft loss and mortality in these patients. Invasive candidiasis is the most common IFI in solid organ transplant recipients. Because of lack of randomized controlled trials, antifungal treatments should be performed as recommended for other immunosuppressed hosts. Drug interactions should be considered when using azol groups. Klimik Dergisi 2019; 32(Suppl. 2): 174-6.

• Publication year

  2020

• Venue

  Klimik Dergisi\/klimik Journal

• Publication date

  2020-01-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.5152/kd.2019.63
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Candida infections in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice

  2019cited by this paper
• Fungal infections in solid organ transplantation: An update on diagnosis and treatment.

  2019cited by this paper
• Cryptococcosis in solid organ transplantation—Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice

  2019cited by this paper
• Interactions between anti‐infective agents and immunosuppressants—Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice

  2019cited by this paper
• Emerging fungal infections in solid organ transplant recipients: Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice

  2019cited by this paper
• Invasive Aspergillosis in solid‐organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice

  2019cited by this paper
• Mold Infections in Solid Organ Transplant Recipients.

  2018cited by this paper
• Approach to the Solid Organ Transplant Patient with Suspected Fungal Infection.

  2016cited by this paper
• Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.

  2016cited by this paper
• ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients

  2016cited by this paper
• Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.

  2016cited by this paper
• Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

  2016cited by this paper
• Solid Organ Transplantasyonunda İmmünsupresyon

  2013cited by this paper
• Epidemiology, outcomes, and mortality predictors of invasive mold infections among transplant recipients: a 10‐year, single‐center experience

  2013cited by this paper
• Pneumocystis jirovecii pneumonia 13 years post renal transplant following a recurrent cytomegalovirus infection

  2012cited by this paper
• Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients

  2010cited by this paper
• Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET).

  2010cited by this paper
• Voriconazole in the treatment of invasive aspergillosis in kidney transplant recipients.

  2007cited by this paper
• Voriconazole in the Treatment of Invasive Mold Infections in Transplant Recipients

  2003cited by this paper
• Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis.

  2002cited by this paper

• No citing papers are available for this paper.